Pfizer Q3 FY17 results (Oct–Dec 2016) and concall

Pfizer's Q3 FY17 was a transition quarter marked by significant structural headwinds, including the discontinuation of the core Corex formulation and the divestment of certain brands. While reported revenue and operating profits were hit by these changes and the external shock of demonetization, the 'Continuing Business' showed resilience with 4% growth. Management is pivoting towards new line extensions (Corex T) and integrating global acquisitions (Meronem) to rebase growth for FY18 and FY19.